Investor''s Presentation

(Formerly – Kilpest India Limited) Ref. No.P-66/2026-27/27 August 13, 2026 The Relationship Manager, Department of Corporate Relations BSE Limited, P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 Dear Sir/Madam, Please find the enclosed herewith Investor’s Presentation / Company Update of Agrochemicals and Diagnostic Kits (Health Care) for your information and necessary action. Thanking You, For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) Nikhil Kuber Dubey Whole Time Director DIN: 00538049 Encl: As above Regd. Office & Factory : 7-C | Industrial Area | Govindpura | Bhopal – 462023 | (M.P.) | INDIA CIN : L24211MP1972PLC001131 Ph.: 91-755-2586536, 2586537 Email : info@kilpest.com Visit us at : www.kilpest.com Since 1972 Investor Presentation August, 2026 Disclaimer This presentation and the accompanying slides (the “Presentation”), which has been prepared by 3B BlackBio Dx Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omissionfrom, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statementsand projections. Financial Highlights – Consolidated – Q1 2026-27 Q1 2025-26 3,349.08 Q1 2026-27 2,223.46 14.76 1,586.35 10.48 1,321.95 1,264.45 897.84 Revenue from Operations Profit Before Tax Profit After Tax EPS Consolidated (In ₹ Lakhs) Q1 2025-26 Q1 2026-27 Revenue from Operations 2,223.46 3,349.08 Profit Before Tax 1,586.35 1,321.95 Profit After Tax 1,264.45 897.84 Paid-Up Equity Share Capital 856.84 856.84 Reserves 26,243.65 26,243.65 EPS 14.76 10.48 * In above numbers, CORIS sales of ₹862.83 Lakh is included ** In above numbers, CORIS negative EBITDA of ₹(352.24) Lakh is included Last Year Q1 figures do not include Coris numbers as the date of consolidation was 29th August 2025. Financial Highlights – Consolidated excl. Coris – Q1 2026-27 2,486.24 Q1 2025-26 2,223.46 Q1 2026-27 1,791.76 1,586.35 1,367.66 1,264.45 14.76 15.96 Revenue from Operations Profit Before Tax Profit After Tax EPS Consolidated (in ₹ Lakhs) Q1 2025-26 Q1 2026-27 Revenue from Operations ₹2,223.46 ₹2,486.24 Profit Before Tax 1,586.35 1,791.76 Profit After Tax 1,264.45 1,367.66 Paid-Up Equity Share Capital 856.84 856.84 Reserves 26,243.65 32,307.03 EPS 14.76 15.96 In above numbers, CORIS figures are not included. Key Highlights – Agrochemicals Division Main Thrust Area of R&D ❑ Development of novel formulations for agriculture and public health which are less harmful and cost effective. ❑ Performance monitoring of existing products/process. ❑ Improvement in existing products/process with a customer driven approach. Future Outlook of Agro-Chemical Division The Agro-Chemical division maintains focus to government procurement, primarily facilitated through electronic tenders on platforms such as GeM, and exports to Bangladesh mainly. Presently, the Agro business operates with minimal debt. Sales within the agrochemical sector remain stable, with vision to only supply to old customers, Govt. tenders for Vector borne disease control & exports. Agrochemicals Exports The export sales of our agrochemicals division amounted to INR 58.99 Lakh in Q1 2026-27 compared to INR 53.58 Lakh in Q1 2025-26. Agrochemicals - Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 • Health & Hygiene 06 • Chelated Zinc 01 • Repellents 03 • Plant Growth Regulators 02 3B BlackBio has been selected as a part of “Select 200 Companies” with the global business potential at DGEMS2023 held in Delhi on 27th October 2023 presented by Forbes India & D Globalist. Financial Highlights: Molecular Diagnostics (MDx) Division Q1 2026-27 Overview – MDx Division ❑ Founded: November 2010 | 15 years in molecular diagnostics ❑ Core Focus: Design, Development & Manufacture of Molecular Diagnostic Kits: • qPCR Assays (TRUPCR®) • Lateral Flow Assays (TRURAPID®) • NGS Assays (TRUNGS®) • Digital PCR Assays (TRUdPCR®) ❑ Product Portfolio: 120+ Molecular Diagnostic Assays Developed ❑ Certifications: ✔ ISO 13485:2016 (BSI, UK) ✔ Licensed by CDSCO, Govt. of India ✔ IVDR compliant (EU 2017/746) ❑ Awards & Recognition: • National MSME Award 2018 (Presented by Hon. President of India) • Outstanding Achievement Award (2017 & 2022) – MP Chambers of Commerce & Industries • Featured in FORBES INDIA DGEMS 2023 – Top 200 Global Potential Companies Overview – MDx Division Well Established PAN-India & Comprehensive Brand Global Presence Molecular Diagnostics Only company to have Product & customer support Well established molecular qPCR Assays, Lateral Flow access available to over diagnostics (MDx) brand Tests and NGS assays 1,000 labs / hospitals in with largest range of Indian available together, providing India across 100+ cities in IVD and CE-IVD Products the most comprehensive India and 70+ countries available molecular diagnostics internationally solutions to customers Our Strategic Priorities Market Penetration: Portfolio Expansion: We aim to boost sales with current Leveraging our R&D strengths, we customers and channel partners by continuously evolve our portfolio – with expanding the range of products within new assays in qPCR, Lateral flow their existing portfolios. immunoassay, NGS. Geographical Reach: Mergers & Acquisitions: We are entering untapped regions In view of our long-term growth strategy, through strategic partnerships with local we are pursuing strategic M&A distributors and direct engagement In opportunities. Our objective is to emerging markets. maximize value for our stakeholders. MDx Growth Canvas excluding Coris 3,125.0 2,142.1 952. [Showing first 8,000 characters — download PDF for full document]